Documente Academic
Documente Profesional
Documente Cultură
DIRECTOR DE TESIS
D.C. ALFREDO TLLEZ VALENCIA
CO-DIRECTORA
D.C. EDNA MADAI MENDEZ HERNANDEZ
presenta:
MIGUEL WONG SERRANO
INTRODUCCION
El desarrollo de acidosis lctica en el
paciente con cncer representa un
marcador de muy mal pronstico, pues
con la administracin de esquemas de
tratamiento, el desenlace con frecuencia
resulta fatal, alcanzando tasas de
mortalidad hasta el 95%.
Gauthier PM, Szerlip HM. Metabolic acidosis in the intensive care unit. Crit Care Clin 2002; 18: 289-308
ANTECEDENTES
ANTECEDENTES
Inegi 2014 ESTADSTICAS A PROPSITO DEL DA MUNDIAL CONTRA EL CNCER INSTITUTO NACIONAL DE ESTADSTICA Y GEOGRAFA
DURANGO DGLO A 4 DE FEBRERO DE 2013
ANTECEDENTES
ANTECEDENTES
Uno de los factores de peor pronstico en el
paciente con diagnstico de cncer es el
desarrollo de:
ACIDOSIS LCTICA
Presencia de lactato sanguneo por encima
de 5 mmol/L
pH menor a 7.3
Gauthier PM, Szerlip HM. Metabolic acidosis in the intensive care unit. Crit Care Clin 2002; 18: 289-308
ACIDOSIS LCTICA
B
1
ACIDOSIS
LCTICA
B
2
B
3
Ruiz J, Ashok K., Hart P. Type B Lactic Acidosis Secondary to Malignancy: Case Report, Review of Published Cases, Insights into Pathogenesis, and
Prospects for Therapy. The Scientific World Journal. 2011; 11: 13161324
ANTECEDENTES
Efecto
Warburg
COMPLEJO PDH
(Jilka et al. 1986; Patel and Roche 1990; Reed et al. 1992). (Gudi et al. 1995; Bowker
Kinley et al. 1998;
COMPLEJO PDH
PIRUVATO DESHIDROGENASA
GLUCOSA
Condicione
s
anaerbica
s
2 ETANOL
Fermentacin
alcohlica
Levaduras en
Ausencia de O2
Glucolisis
10 reacciones
sucesivas
PIRUVATO
2 CO2
Condiciones
aerbicas
2 COA2
2 ACETIL-SCOA
Respiracion Celular
Seres en presencia de O2
Condiciones
anaerbicas
2
LACTATO
Fermentacin
Lctica
Tejido muscular
En ausencia de O2
TNF
Elevadas
concentraciones
de TNF inhiben
la actividad del
complejo
Piruvato
deshidrogenasa
Producir necrosis hemorrgica de tumores,
en injuria tisular y shock, gracias a sus
Propiedades proinflamatorias sobre el
endotelio vascular.
Jos Manuel Fragoso Lona1, Mnica Sierra Martnez2, Gilberto Vargas Alarcn1,3, Anglica Barrios Rodas1
y Julin Ramrez Bello4*El factor de necrosis tumoral (TNF-) en las enfermedades cardiovasculares: biologa molecular y gentica Gaceta Mdica de Mxico. 2013;149:521-30
(Arend WP et al, 1995; Dealtry GB et al, 1987)
Ruiz J, Ashok K., Hart P. Type B Lactic Acidosis Secondary to Malignancy: Case Report, Review of Published Cases, Insights into Pathogenesis, and Prospects for Therapy. The Scientific
World Journal. 2011; 11: 13161324
Impacto psicolgico.
Prdida de habilidades
sociales
Independencia
Incapacidad laboral
Tratamiento
- Medicamentos
Cuidadores
Ruiz J, Ashok K., Hart P. Type B Lactic Acidosis Secondary to Malignancy: Case Report, Review of Published Cases, Insights into Pathogenesis, and
Prospects for Therapy. The Scientific World Journal. 2011; 11: 13161324
JUSTIFICACIN
Ruiz J, Ashok K., Hart P. Type B Lactic Acidosis Secondary to Malignancy: Case Report, Review of Published Cases, Insights into Pathogenesis, and
Prospects for Therapy. The Scientific World Journal. 2011; 11: 13161324
Ruiz J, Ashok
Ruiz J, Ashok K., Hart P. Type B Lactic Acidosis Secondary to Malignancy: Case Report, Review of Published Cases, Insights into Pathogenesis, and
Prospects for Therapy. The Scientific World Journal. 2011; 11: 13161324
PREGUNTA DE INVESTIGACIN
OBJETIVO GENERAL
OBJETIVOS ESPECIFICOS
MATERIAL Y METODOS
Diseo:
Casos y controles
Grupos de Estudio:
Definicin de caso: Pacientes con diagnstico
de tumor slido que presenten acidosis lctica
tipo B
Definicin de control: Pacientes con
diagnostico de tumor slido sin presencia de
acidosis lctica B
MATERIAL Y MTODOS
VARIABLES DE ESTUDIO
MATERIAL Y METODOS
PROCEDIMIENTOS
ANALISIS ESTADISTICO
CRONOGRAM
Fecha
Redaccin y
revisin de
protocolo
Aprendizaje
de tcnicas
de
laboratorio
Toma de
muestras
Procesamie
nto de
muestras
Anlisis de
muestras
Anlisis
estadstico
Resultados
DESGLOSE FINANCIERO
Con el recurso
solicitado al Fondo de
Investigacin del
Instituto de
Investigacin Cientfica
se destinara
especficamente a
efectuar las
mediciones de lactato
y el anlisis de la
expresin de los genes
que codifican para las
enzimas
concentraciones
INSUMO
PRECIO
CANTIDAD
UNITARIO
TOTAL
por
$20353.00
mtodo
colorimtrico
Sondas
para
evaluar
el $7000.00
$35,000
$13,000
de
$13,000
$5647.00
transferencia,
TOTAL:
$80,000.00 aprox
CONSIDERACIONES
TICAS.
AVANCES
Reproductor
Digestivo
Otros
Tabla 1. Anlisis comparativo de las principales caractersticas gasomtricas de los grupos de estudio.
Casos
Controles
12
7.39(7.30-7.48)
7.41(7.26-7.48)
0.902
Pco2, mm Hg
33(23-28)
27.2(24.3-28)
0.482
Po2, mm Hg
82.6(59.0-106.3)
64.8(53-78.9)
0.262
21.5(13.3-23)
18.3(10.9-21.0)
0.261
3.2(2.2-5.0)
1.2(0.95-1.49)
0.000
n
pH
HCO3, mEq/L
cido lctico, mmol/L
Tabla 2. Anlisis comparativo de las principales caractersticas bioqumicas de los grupos de estudio.
Casos
Controles
12
1.4(0.5-1.8)
1.05(0.6-3.7)
0.885
48(28-59)
46(25.7-162.6)
0.456
165(129-201)
98(68.7-1165)
0.061
9.5(9.4-9.6)
4.28(4.27-4.29)
0.317
Na, mEq/L
137.7(137-140)
140.4(136-147.2)
0.482
Ca, mEq/L
0.87(0.50-1.05)
0.83(0.78-1.02)
0.943
Cl, mEq/L
111.5(105.7-122)
116(108.5-119)
0.529
K, mEq/L
3.9(3.1-4.3)
3.3(3.0-4.2)
0.791
n
Creatinina, mg/dl
Urea, mg/dl
Glucosa, mg/dl
cido rico, mg/dl
Tabla 3. Anlisis comparativo de las pruebas de funcionamiento heptico de los grupos de estudio.
Casos
Controles
12
TGO, U/l
44(25-111)
33.5(19.5-176.7)
0.921
TGP, U/l
39(28-111)
42.5(15.7-54.37)
0.921
215(102-219)
122.5(68-236)
0.630
Albmina, mg/dl
3.2(2.3-3.2)
3.6(2.2-4.4)
0.667
Globulina, mg/dl
3.2(2.8-3.6)
1.9(1.6-2.9)
0.183
0.6(0.5-0.6)
0.55(0.17-0.85)
0.905
0.4(0.1-0.5)
0.40(0.20-0.95)
0.571
0.2(0.1-0.5)
0.20(0.10-0.25)
0.786
Casos
Controles
12
Leucocitos K/l
14.8(8.0-31.6)
9.7(59-12.9)
0.250
Eritrocitos, M/l
4.4(3.8-5.1)
3.3(2.8-4.2)
0.027
12.1(10.2-17.4)
11.7(10.4-14)
0.733
36.5(31-52.2)
34(31-43)
0.591
MCV, fL
90.8(83.5-95.5)
89.3(86.8-95.4)
0.884
HMC
28.6(28.4-33.0)
30(28.5-30.5)
0.660
CHCM
33.9(31.8-34.4)
33.8(32.2-34.7)
0.827
309(196.5-488.2)
197(157.2-288.5)
0.125
Hemoglobina, g/dl
Hematocrito, %
Plaquetas, K/ l
Los valores que se muestran son mediana (rango intercuartlico). x Prueba U de Mann Whitney
BIBLIOGRA
FA
Udayakumar N, et al. A typical presentation of acute myeloid leukemia. J Cancer Res Ther. 2006;
2(2):82-84.
Field M, Block JB, Rall DP. Lactic acidosis in acute leukemia. Clin Res 1963; 11:193-197
Munoz J, Khushman M, Hanbali A, et al. Severe lactic acidosis in a patient with metastatic prostate
cncer 2011; 7(2): 201-202
Sillos E, Shenep J, Burghen G, et al. Lactic Acidosis: A Metabolic Complication of Hematologic
Malignancies. Cancer. 2001; 92(9): 2237-2246
Gauthier PM, Szerlip HM. Metabolic acidosis in the intensive care unit. Crit Care Clin 2002; 18: 289308
Ruiz J, Ashok K., Hart P. Type B Lactic Acidosis Secondary to Malignancy: Case Report, Review of
Published Cases, Insights into Pathogenesis, and Prospects for Therapy. The Scientific World Journal.
2011; 11: 13161324
Rovelli A, Bonomi M, Murano A, et al. Severe lactic acidosis due to thiamine deficiency after bone
marrow transplantation in a child with acute monocytic leukemia. Haematologica 1990; 75: 579-581
Warburg O, Posener K, Negelein E. Ueber den stoffwechsel der tumoren. Biochem 1924; 152: 319344
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg Effect: the metabolic
requirements of cell proliferation. Science 2009; 324: 1029-1033
Mndez-Hernndez EM, Acua-Valerio JF, Ardavin-Iduarte JM, Loaeza A, Vargas-Ruiz AG. Acidosis
lctica y leucemia linfoblstica aguda: presentacin de un caso, Rev Mex Hematol 2008; 9(1)
De Groot R, Sprenger R, Imholz A. et al. Type B lactic acidosis in solid malignancies. The Journal of
Medicine 2011; 69(3): 120-123.
Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells. Isolation, sequence, and
activity of the promoter for type II hexokinase. J. Biol. Chem. 1995; 270(28): 16918-16925
Jeffrey J, Sorensen G, Sorensen M. Burkitts lymphoma presenting with lactic acidosis and
hypoglycemia. Leukemia & Lymphoma. 2005; 46(2):281 283.
Di Comite G, Dagna L, Piatti P, et al.Hipoglycaemia and Lactic Acidosis in a MALT non Hodgkins
Lymphoma. Leukemia & Lymphoma.2002; 43(6): 1341-1342.
Khalil Diab, Kenneth S. et al. An 81-Year-Old Man With Lactic Acidosis, Refractory Hypoglycemia, and
Lymphocytosis. Chest 2008; 133; 306-310.
Hideichi M, Kazuo N, Yoshiaki I, et al. Lactic Acidosis and Hypoglycemia Associated with Acute
Luscri N, Mauer M, Sarafoglou K, et al. Lactic Acidosis and Hypoglycemia With ALL Relapse Following
Engrafted Bone Marrow Transplant. Pediatr Blood Cancer 2009; 53:223225.
During J, Fiedler W, de Wit M, et al. Lactic acidosis and hypoglycemia in a patient with high-grade
non-Hodgkins lymphoma and elevated circulating TNF-alpha. Ann Hematol 1996; 72: 97-99
Su Cho H, Oh Choi S, Chun Seol D, et al. A case of acute lymphoblastic leukemia accompanied with
lactic acidosis and kidney enlargement. Korean J Hematol 2008; 43(3): 170-173
Jensen JC, Buresh C, Norton JA. Lactic acidosis increases tumor necrosis factor secretion and
transcription in vitro. J Surg Res 1990; 49: 350-353
Svahn J, Schiaffino M, Caruso U, et al. Severe lactic acidosis due to thiamine deficiency in a patient
with B-cell leukemia/lymphoma on total parenteral nutrition during high-dose methotrexate therapy.
J Pediatr Hematol Oncol 2003; 25: 965-968
Cameron JM, Levandovskiy V, Mackay N, Tein I, Robinson BH. Deficiency of pyruvate dehydrogenase
caused by novel and known mutations in the E1 alpha subunit. Am. J. Med. Genet. 2004; 131:5966.
Magner M, Vinov K, Tesaov M, et. Al. Two Patients with Clinically Distinct Manifestation of
Pyruvate Dehydrogenase Deficiency Due to Mutations in PDHA1 Gene. Prague Medical Report 2011;
112(1):1828
Block JB. Lactic acidosis in malignancy and observations on its possible pathogenesis. Ann NY Acad
Sci 1974; 230: 94-102
Celalettin U, Fall P, Szerlip H, et al. Multiple Myeloma Associated with Lactic Acidosis. Leukemia &
Limphoma. 2002; 43(12): 2395-2397.
Huei Chan F, Carl D, Lyckholm L. Severe Lactic Acidosis in a Patient with B-Cell Lymphoma:A Case
Report and Review of the Literature. Hindawi Publishing Corporation Case Reports in Medicine
2009:1- 6.
Prikis M, Bhasin V, Young M. Sustained low-efficiency dialysis as a treatment modality in a patient
with lymphoma-associated lactic acidosis. Nephrol Dial Transplant (2007); 22: 23832385.
De Keulenaer B, Van Outryve S, De Backer A. Symptomatic lactic acidosis due to relapse of T-cell
acute lymphoblastic leukaemia in the kidney. Nephrol Dial Transplant (2003); 18: 12141216.
Hae Seung L, Hyun Jung K, Soojeong C. A Case of Type B Lactic Acidosis in Acute Leukemia. Yonsei
Med. 2010; 51(3): 460-462.
Young H, Singh S, Greystoke B, et al. Lactic acidosis expediting a diagnosis of acute lymphoblastic
leukaemia. BMJ Case Rep. 2009;1601
Ohtsubo K , Imamur A, Seki R, et al. Blastoid Variant of Mantle Cell Lymphoma with Lactic Acidosis: A
Case Report. International Journal of Hematology. 2004; 80: 428-431.